Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Eitemau Tebyg

• Precision medicine on a budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs
  gan: Alexandra Lindsey Djomkam Zune, et al.
  Cyhoeddwyd: (2025-08-01)
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
  gan: Hoffmann, Markus, et al.
  Cyhoeddwyd: (2020)
• Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon
  gan: Djomkam, Alexandra Lindsey Zune, et al.
  Cyhoeddwyd: (2019)
• Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon
  gan: Alexandra Lindsey Zune Djomkam, et al.
  Cyhoeddwyd: (2019-01-01)
• Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
  gan: Burgueño, Juan F, et al.
  Cyhoeddwyd: (2020)